

## WOAH Reference Laboratory annual reports (RINDERPEST)

### Activities in 2024

Name (including Title) of Head of Laboratory (Responsible Official):

Dr Ken KATSUDA, Director of the National Institute of Animal Health, National Agriculture and Food Research Organization (NARO)

Name (including Title and Position) of WOAH Reference Expert:

Dr Takehiro KOKUHO, Executive Research Scientist

Email address:

Kokuho.takehiro756@naro.go.jp

Address of laboratory:

6-20-1 Josuihoncho, Kodaira, Tokyo, 187-0022 JAPAN

Website:

<https://www.naro.go.jp/english/laboratory/niah/index.html>

Telephone:

+81 42 321 1466

Fax:

+81 42 325 5122

### A: Maintaining Scientific and Technical Skills

1. Did your laboratory perform relevant diagnostic tests for purposes such as disease, diagnosis, screening of animals for export, surveillance, etc. (not for quality control, proficiency testing or staff training)
  - a. For the specified disease?
  - b. For closely related diseases or pathogens?

Disease	Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of tests performed last year	
			Nationally	Internationally
NA				

--	--	--	--	--

2. Did your laboratory produce, supply, or import standard reference reagents officially recognised by the WOAHA for the specified disease or for closely related diseases?

Type of Reagent Available	Related diagnostic test	Produced/Supplied/Imported	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	Name of recipient WOAHA member countries
NA					

3. Did your laboratory supply, exchange or receive standard reference reagents and/or other diagnostic reagents for the specified disease

Type of reagent	Related diagnostic test	Supplied by your lab, exchanged or received	Amount	Name of recipient or supplier member country
NA				

4. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHA Member Country for the specified disease or for closely related diseases?

Name of the WOAHA member country receiving the technical consultancy	Purpose	How the advice was provided
NA		

5. What method of dissemination of information is most often used by your laboratory? (please provide information on activities for other diseases relevant to maintaining capability for specified disease) [a: Articles published in peer-reviewed journals; b: International conferences; c: National conferences; d: Other]

a: Articles published in peer-reviewed journals

b: International conferences

d: In-house seminars

6. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA Member Countries?

☐ Yes

☐ No

7. Did your laboratory implement activities to ensure ongoing capability for the designated disease or closely related disease in the event of loss of the key staff including the WOA Reference Expert?

Activity	Description
NA	

## B: Laboratory Systems

8. Does your laboratory have a Quality Management System certified according to an International Standard? If YES indicate the name of the quality management system adopted or currently in place. Also attach a scanned certificate of the system.

Yes

ISO/IEC 17025:2017 (Accreditation certificate (PDF) attached to this report)

9. Is your laboratory accredited by an international accreditation body? If 'yes' indicate test for which your laboratory is accredited and name of the accreditation body.

Yes

Reverse Transcription (RT)-PCR accredited by Japan Accreditation Board (JAB)

10. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

☒ Yes

☐ No

11. Does your laboratory have a biosecurity system in place to ensure security for the pathogen and materials that may contain the infectious pathogen?

☒ Yes

☐ No

### C: Capability to Respond to a Suspected Case

12. In the last year, did your laboratory perform diagnostic tests for the specified pathogen and the disease in order to confirm ongoing capability?

Diagnostic Test	Indicated in WOA H Manual (Yes/No)	Total number of tests performed last year
Proficiency testing for the diagnosis of rinderpest (Sham testing)	No	10

13. Did your laboratory produce vaccines for the specified disease or similar diseases?

Disease	Amount supplied nationally or internationally
No (in 2024)	We maintain the international reserve of rinderpest vaccine (963,600 doses of LA-AKO vaccine) at the request of FAO.
We produced 100,000 doses in 2023 and are scheduled to produce 70,000 doses in 2025 under the LOA signed between our lab and the FAO.	

14. Did your laboratory organise or participate in inter-laboratory proficiency tests with any other laboratories for the specified disease or similar diseases?

Role of your laboratory (organiser or participant)	Disease	Test	Number of participating laboratories	Regions of participating WOA H member countries
No				


## D: Networks and Linkages

15. Did your laboratory organise or participate in scientific meetings for the specified disease?

Title of event	Date	Location	Role (Organiser, speaker, presenter)	Title of work presented
Rinderpest holding facility network teleconference	Jan 30, 2024	Web	participant	
Rinderpest holding facility network teleconference	Feb 25, 2025	Web	participant	

16. Did your laboratory exchange information with other WOA Reference Laboratories designated for the same pathogen or disease?

☒ Yes

☐ No

17. Was your laboratory involved in maintaining a network with WOA Reference Laboratories designated for the same pathogen or disease?

☒ Yes

☐ No

18. Did your laboratory place expert consultants at the disposal of the WOA?

☐ Yes

☒ No

19. Did your laboratory carry out activities to raise awareness and improve capability for this disease in other member countries?

Description of activity	Date	Member countries
No		

### E: Biosafety

20. What level of biocontainment is used in your laboratory for (a) storage and (b) handling of potentially infectious material for the specified disease?

Kodaira, Tokyo (RHF category A): (a) BSL3, (b) BSL3  
Tsukuba, Ibaraki (RHF category B): (a) BSL2, (b) BSL2

21. Does your laboratory maintain a structured risk assessment for work with potentially infectious material for the specified disease?

☒ Yes

☐ No

22. Was your laboratory's risk assessment for work with potentially infectious material reviewed in the past year?

☒ Yes

☐ No

23. Does your laboratory have an emergency response plan for biosafety incidents involving potentially infectious material for the specified disease?

☒ Yes

☐ No

## F: Research

24. Did your laboratory develop new diagnostic methods for the designated pathogen or disease, or a similar disease?

Disease	Diagnostic Method	Description
No		

25. Did your laboratory participate in international scientific studies in collaboration with WOA Member Countries other than your own?

Title of study	Duration	Purpose of study	Partners (Institutions)	WOAH Member Countries Involved other than your Country
Collaborative Research Agreement	Jul 2022-Mar 2027	Studies on the immune responses of animal infectious diseases	National Institute of Veterinary Research	Vietnam
Tripartite Research Cooperation Agreement	Oct 17, 2024-Oct 16, 2025	Comprehensive collaboration on African Swine Fever research under	National Institute of Veterinary Research Veterinary Research Institute	Vietnam Chinese Taipei

26. Did your laboratory collaborate with other WOA Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest or a similar pathogen?

Title of Project or Contract	Scope	Name(s) of relevant WOA Reference Laboratories
No		

27. Additional comments regarding your report (if any):

We are processing the MTA between our lab and the Pirbright Institute, UK, for the provision of LA-AKO vaccine-immunised cattle sera to evaluate the new RP-cELISA.